BI836826

· Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI836826, covering 2020-08-20 to 2020-08-20. Get the full timeline:

Most recent: Clinical Trial Update: BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) [Phase 1]